Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ – Get Free Report) was the target of a large decrease in short interest in July. As of July 15th, there was short interest totaling 76,263 shares, a decrease of 87.3% from the June 30th total of 602,285 shares. Currently, 1.6% of the company’s stock are short sold. Based on an average trading volume of 1,095,213 shares, the days-to-cover ratio is presently 0.1 days.
Creative Medical Technology Trading Down 3.4%
Shares of NASDAQ CELZ traded down $0.03 during mid-day trading on Monday, reaching $0.78. The company had a trading volume of 71,801 shares, compared to its average volume of 1,497,429. The firm has a 50 day simple moving average of $1.69 and a two-hundred day simple moving average of $1.92. Creative Medical Technology has a 52-week low of $0.77 and a 52-week high of $6.25. The stock has a market cap of $3.71 million, a P/E ratio of -0.37 and a beta of 1.89.
Creative Medical Technology (NASDAQ:CELZ – Get Free Report) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.01. On average, equities analysts expect that Creative Medical Technology will post -1.14 EPS for the current year.
Analyst Upgrades and Downgrades
Get Our Latest Stock Analysis on CELZ
Institutional Trading of Creative Medical Technology
An institutional investor recently bought a new position in Creative Medical Technology stock. Jane Street Group LLC purchased a new position in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned 1.17% of Creative Medical Technology as of its most recent SEC filing. 1.42% of the stock is currently owned by hedge funds and other institutional investors.
Creative Medical Technology Company Profile
Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.
The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.
Featured Stories
- Five stocks we like better than Creative Medical Technology
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
- A $1.5 Billion Wake-Up Call for Every AI Company on Wall Street
- AMD’s AI Bubble Could Burst Into Explosive Upside
- Atlassian’s AI Pivot Is Starting to Challenge Wall Street’s Bear Case
Receive News & Ratings for Creative Medical Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creative Medical Technology and related companies with MarketBeat.com's FREE daily email newsletter.
